Graft-versus-host disease (GVHD) is one of the most important complications following allogeneic hematopoietic cell transplantation (HCT). It occurs when immunocompetent donor T cells recognize the recipient's tissues as foreign and mount an immune attack against them. Understanding the early signs, organ-specific concerns, underlying biology, treatment algorithms, and—critically—who should follow these patients long-term is essential for every clinician involved in the care of transplant survivors.
---
THE FIRST SYMPTOMS AND SIGNS: WHAT TO WATCH FOR
The earliest and most common manifestation of acute GVHD is a pruritic maculopapular skin rash, often appearing on the palms, soles, and ears, typically coinciding with engraftment of donor cells. At onset, the skin is involved in approximately 81% of patients, the gastrointestinal (GI) tract in 54%, and the liver in 50%.
GI involvement usually presents as nausea, anorexia, vomiting, watery or bloody diarrhea, and crampy abdominal pain. Diarrhea can be secretory and voluminous—exceeding 2 liters per day in severe cases. Liver disease manifests as cholestatic hyperbilirubinemia with elevated alkaline phosphatase and aminotransferases.
In severe cases, the skin rash can progress to total-body erythroderma with bullae formation and desquamation. Severe GI GVHD with mucosal ulceration and bleeding carries a particularly poor prognosis.
Acute GVHD is graded from I (mild) to IV (very severe) based on the extent of involvement of these three target organs. Among all patients undergoing allogeneic HCT, 30–50% develop some degree of acute GVHD, and approximately 14% develop severe (grade III–IV) disease.
Chronic GVHD, which typically develops 3 months to 1.5 years after transplantation, has a broader range of manifestations. Clinical signs are often first seen in the buccal mucosa and can include lichen planus-like changes, xerostomia, sclerotic skin features, nail dystrophy, bronchiolitis obliterans, and—critically for eye surgeons—severe ocular surface disease.
---
WHY EYE SURGEONS SHOULD PAY ATTENTION
Ocular GVHD (oGVHD) is one of the most prevalent manifestations of chronic GVHD, affecting 60–90% of patients with chronic disease. The hallmark is keratoconjunctivitis sicca (dry eye disease), driven by immune-mediated destruction and fibrosis of the lacrimal glands, meibomian glands, cornea, and conjunctiva.
Key ocular manifestations include:
- Dry eye disease—the most common presenting feature, resulting from lacrimal gland fibrosis and tear film deficiency
- Meibomian gland dysfunction—contributing to evaporative dry eye
- Cicatricial conjunctivitis—scarring of the conjunctival surface
- Confluent punctate keratopathy—corneal epithelial damage
- Superior limbic keratoconjunctivitis—a marker of augmented ocular surface distress
- Blepharitis—eyelid inflammation with erythema and edema
- Photophobia and periorbital hyperpigmentation
In the most severe cases, oGVHD can lead to corneal perforation and irreversible vision loss. Ocular manifestations may even precede other systemic GVHD findings and can serve as a poor prognostic indicator for mortality.
The NCCN Guidelines recommend ophthalmologic assessment at appropriate intervals beginning 6–12 months post-transplant. Patients with chronic ocular GVHD may benefit from artificial tears, autologous serum drops, punctal plugs, gas-permeable scleral lenses, and cholinergic agents (cevimeline or pilocarpine) for severe sicca.
Additional concerns for eye surgeons include:
- Cataracts—associated with glucocorticoid treatment for GVHD, busulfan conditioning, and total body irradiation (TBI)
- Glaucoma—a late complication of TBI or systemic/topical corticosteroid therapy, with children at greater risk
- Infectious complications—including CMV retinitis, bacterial, fungal, and toxoplasma infections
- [Limbal stem cell deficiency](https://www.openevidence.com/rare-disease/limbal-stem-cell-deficiency)—which may require conjunctival and limbal transplantation from the same living-related bone marrow donor
The NIH consensus criteria grade ocular GVHD severity from Score 0 (no symptoms) to Score 3 (severe dry eye symptoms significantly affecting activities of daily living, requiring special eyewear, inability to work, or loss of vision due to keratoconjunctivitis sicca).
---
GVHD AFTER BONE MARROW TRANSPLANT FOR LEUKEMIA: ABSOLUTELY YES
GVHD is not only possible but expected after allogeneic bone marrow transplant for leukemia—it is the most common life-threatening complication of this procedure. Allogeneic HCT is a well-established curative treatment for acute myeloid leukemia (AML), [acute lymphoblastic leukemia](https://www.openevidence.com/rare-disease/acute-lymphoblastic-leukemia) (ALL), and chronic myeloid leukemia (CML), among other hematologic malignancies.
Without prophylactic immunosuppression, most allogeneic bone marrow transplantations will be complicated by GVHD. Even with prophylaxis, the majority of adults develop some degree of acute GVHD. The incidence ranges from 35–45% in recipients of fully matched sibling donor grafts to 60–80% in recipients of one-antigen HLA-mismatched unrelated donor grafts.
Importantly, GVHD has a dual nature in leukemia patients. While it causes significant morbidity and mortality, it is also associated with a graft-versus-leukemia (GVL) effect—donor immune cells that attack the host also attack residual leukemic cells. This accounts for reduced relapse rates in patients who develop GVHD compared to those who do not. However, more severe GVHD does not necessarily enhance antitumor effects and dramatically increases transplant-related mortality.
---
AGE AND GVHD: WHO IS MOST AT RISK?
Older recipient age is one of the single most important risk factors for developing GVHD, particularly chronic GVHD. In a large single-center analysis of 551 bone marrow transplant recipients, high recipient age was identified as the most significant risk factor for chronic GVHD.
Key age-related findings include:
- Both acute and chronic GVHD are more frequent in older patients
- In pediatric populations, the incidence of moderate/severe chronic GVHD increases with recipient age, even after adjusting for patient, donor, and transplant characteristics
- The mean age of bone marrow transplant patients who develop chronic GVHD is approximately 53 years
- Over the past three decades, the median age at transplantation has increased from 32 to 54 years, reflecting expanded indications and use of reduced-intensity conditioning in older patients
- Chronic GVHD is most likely to develop in older patients and in those with preceding acute GVHD
Other major risk factors beyond age include:
- Degree of HLA mismatch between donor and recipient
- Use of an unrelated donor
- Female donor for a male recipient
- Use of peripheral blood stem cells (rather than bone marrow) as the graft source
- Intensity of the conditioning regimen
- Prior episode of acute GVHD (for chronic GVHD)
---
THE PATHOPHYSIOLOGY: HOW GVHD DEVELOPS
The pathophysiology of GVHD was first conceptualized by Billingham in the 1960s, who formulated three requirements: (1) the graft must contain immunologically competent cells (T cells); (2) the recipient must express tissue antigens not present in the donor; and (3) the recipient must be unable to mount an effective response to eliminate the transplanted cells.
Acute GVHD progresses through three sequential phases:
Phase 1—Activation of Antigen-Presenting Cells (APCs): The conditioning regimen (chemotherapy and/or radiation) damages host tissues, particularly the GI tract. Damaged tissues release "danger signals"—damage-associated molecular patterns (DAMPs) such as ATP, uric acid, IL-33, and HMGB1, as well as proinflammatory cytokines (TNF-α, IL-1, IL-6). Disruption of the intestinal mucosal barrier allows translocation of pathogen-associated molecular patterns (PAMPs) like lipopolysaccharide from gut bacteria. These signals activate host APCs and upregulate MHC antigens and costimulatory molecules.
Phase 2—Donor T-Cell Activation, Proliferation, and Differentiation: Donor T cells interact with activated host APCs in secondary lymphoid tissue, particularly in the GI tract. T cells recognizing host MHC or minor histocompatibility antigens become activated, proliferate, and differentiate along pathogenic Th1 and Th17 paradigms. CD4+ T cells respond to MHC class II differences, while CD8+ T cells respond to class I differences. Costimulatory signals amplify this response.
Phase 3—Target Tissue Destruction: Activated donor T cells migrate to target organs (skin, liver, GI tract) and cause tissue damage through multiple mechanisms: FAS ligand expression, release of granzyme B and perforin, and secretion of cytotoxic cytokines like TNF-α. The result is epithelial apoptosis—the hallmark histological finding of acute GVHD.
Chronic GVHD has a more complex immunopathology involving both T cells and B cells, macrophages, and fibroblasts. It progresses through a similar three-phase model but with distinct features:
1. Acute inflammation and tissue injury from conditioning and acute GVHD, including thymic damage that impairs central tolerance
2. Immune dysregulation—impaired thymic selection allows autoreactive and alloreactive T cells to escape deletion; elevated B-cell activating factor (BAFF) supports survival of autoreactive B cells; defective regulatory T-cell recovery contributes to sustained alloimmunity
3. Aberrant tissue repair and fibrosis—activated macrophages secrete PDGF-α and TGF-β, driving fibroblast activation and extracellular matrix deposition, resulting in the sclerotic features characteristic of chronic GVHD
Recent advances have highlighted the role of T-cell exhaustion as a central checkpoint: while terminal exhaustion promotes tolerance, early calcineurin inhibitor administration may suppress terminal exhaustion and drive accumulation of transitory exhausted T cells that mediate chronic GVHD. This insight helps explain why post-transplant cyclophosphamide-based platforms, which permit donor T cells to undergo exhaustion before calcineurin inhibitor initiation, are associated with reduced chronic GVHD rates.
---
COMPREHENSIVE TREATMENT ALGORITHMS
OCULAR GVHD TREATMENT ALGORITHM
All patients with ocular GVHD receive baseline therapy consisting of preservative-free artificial tears and lid hygiene. Treatment then escalates in a stepwise manner based on severity.
Mild Ocular GVHD (NIH Score 1)
- Preservative-free artificial tears (≤3 times daily)
- Lid hygiene and warm compresses for meibomian gland dysfunction
- Punctal plugs (temporary silicone plugs initially to assess for epiphora risk)
Moderate Ocular GVHD (NIH Score 2)
Add the following to baseline therapy:
- Topical cyclosporine A 0.1% (Ikervis)—used in >90% of patients, though only two-thirds tolerate it due to burning/stinging
- Topical tacrolimus 0.05%—superior to topical steroids in reducing corneal staining (55% vs 23% reduction) without IOP elevation
- Lifitegrast 5%—FDA-approved LFA-1 antagonist showing 44% improvement in NIH severity scores
- Autologous serum eye drops (20-50%)—used in 25% of patients; improves symptoms and corneal staining
- Permanent punctal occlusion (thermal or laser cautery after trial with plugs)
Severe Ocular GVHD (NIH Score 3)
Requires aggressive multimodal therapy:
- All of the above plus:
- Topical corticosteroids—80% of patients require at least intermittent use for acute flares; only 12% need continuous therapy
- Medium-to-high potency (triamcinolone, clobetasol) for body
- Low potency (hydrocortisone) for face/eyelids
- Critical warning: Avoid topical NSAIDs—associated with high rates of corneal ulceration and perforation
- Scleral contact lenses—most effective long-term treatment for severe dry eye and superior limbic keratoconjunctivitis (SLK)
- 56% of wearers wish they had been recommended sooner
- 63% of non-wearers had never heard of them
- Provide continuous fluid reservoir and corneal protection
- Systemic cholinergic agents for severe sicca:
- Cevimeline or pilocarpine—stimulate lacrimal secretion
- Pooled human immunoglobulin eye drops—for refractory cases
- Amniotic membrane transplantation—for persistent epithelial defects
- Tarsorrhaphy (partial)—for exposure keratopathy unresponsive to other measures
Critical Considerations for Eye Surgeons
Ocular GVHD can lead to vision-threatening complications:
1. Corneal perforation—occurs in 23.6% of severe cases at median 39 months post-transplant
2. Limbal stem cell deficiency—may require conjunctival/limbal transplantation from the same bone marrow donor
3. Cataracts—from steroids, busulfan, or total body irradiation
4. Glaucoma—from systemic/topical steroids or TBI (children at higher risk)
5. Infectious keratitis—risk increased by immunosuppression and ocular surface breakdown
Timing of ophthalmologic evaluation: NCCN recommends screening at 6-12 months post-transplant and at appropriate intervals thereafter.
Ocular GVHD often emerges during systemic immunosuppression tapering—75% of cases diagnosed within first 14 months, with 25% occurring after complete discontinuation of systemic therapy. This means isolated ocular disease can occur (18% of cases) even without systemic GVHD.
SYSTEMIC GVHD TREATMENT ALGORITHMS
ACUTE GVHD TREATMENT
Grade I (Mild)—Skin only, 50% BSA
- Continue or restart original immunosuppressive agent (tacrolimus or cyclosporine)
- Topical steroids (triamcinolone, clobetasol) ± topical tacrolimus
- Medium-to-high potency except face/intertriginous areas (use hydrocortisone)
- Antihistamines for pruritus
- Observe if asymptomatic or stable
Grade II-IV (Moderate to Severe)
First-line therapy:
- Continue/restart original immunosuppressive agent (or escalate to therapeutic level)
- Systemic corticosteroids:
- Upper GI only: 0.5-1 mg/kg/day methylprednisolone + topical GI steroids (beclomethasone or budesonide)
- Skin/lower GI/liver: 1-2 mg/kg/day methylprednisolone (consider 1 mg/kg for grade II)
- No role for doses >2 mg/kg/day
- ± Topical steroids as adjunct
- Alternative: Sirolimus for standard-risk acute GVHD
Response assessment at 5-7 days:
- Response = complete resolution OR improvement in ≥1 organ without progression elsewhere → Taper steroids
- No response (steroid-refractory) → Add second-line agent
STEROID-REFRACTORY ACUTE GVHD
FDA-approved Category 1 agent:
- Ruxolitinib (JAK1/JAK2 inhibitor)—approved for age ≥12 years
- Superior overall response and failure-free survival vs. best available therapy
- European consensus: strongly recommended as first choice for SR-aGVHD
Alternative agents (alphabetical):
- Alemtuzumab, Alpha-1 antitrypsin, ATG, Basiliximab
- Calcineurin inhibitors (tacrolimus, cyclosporine)
- Etanercept, Extracorporeal photopheresis (ECP)
- Infliximab, mTOR inhibitors (sirolimus)
- Mycophenolate mofetil, Pentostatin, Tocilizumab
- Vedolizumab
Pediatric patients 12 years: Remestemcel-L (mesenchymal stromal cells)—first FDA-approved therapy for SR-aGVHD in children
CHRONIC GVHD TREATMENT
First-Line Therapy
Standard approach:
- Continue or restart original immunosuppressive agent
- Systemic corticosteroids 0.5-1 mg/kg/day (methylprednisolone or prednisone equivalent)
- Dose may vary based on organs involved, severity, comorbidities
- Alternative: Sirolimus + prednisone
- ± Topical steroids as clinically indicated (skin, oral, ocular)
- For lung involvement (bronchiolitis obliterans): FAM regimen
- Fluticasone (inhaled) + Azithromycin + Montelukast
- Note: Azithromycin for treatment only, NOT prophylaxis (increased relapse risk)
Glucocorticoid monotherapy remains the standard—all attempts to add other agents (mycophenolate, cyclosporine, azathioprine, thalidomide, hydroxychloroquine) to first-line steroids have failed to show benefit.
Response assessment at ≥1 month:
- Response → Taper steroids as clinically feasible
- No response (steroid-refractory) → Add second-line systemic agent
STEROID-REFRACTORY CHRONIC GVHD
FDA-approved Category 1 agent:
- Ruxolitinib (JAK1/JAK2 inhibitor)
- REACH3 trial: 50% overall response vs. 26% with control therapy at week 24
- Doubled failure-free survival
- Significant symptom improvement on Lee Symptom Scale
- European consensus: Primary recommendation for SR-cGVHD regardless of severity or organ involvement
- Allows substantial steroid tapering/discontinuation
Other FDA-approved agents (in order of approval):
1. Ibrutinib (BTK/ITK inhibitor)—age ≥1 year
- 67% overall response rate in phase 2 trial
- 71% sustained response ≥20 weeks
- Caution: Arrhythmias, bleeding risk
- Reserved for second-line (not beneficial when added to first-line steroids)
2. Belumosudil (ROCK2 inhibitor)—age ≥12 years
- Approved after ≥2 prior lines of therapy
- Low toxicity profile
- Emerging data on combination with ruxolitinib
3. Axatilimab (anti-CSF-1R)—weight ≥40 kg
- Approved after ≥2 prior lines of therapy
- Newest FDA-approved option (2025)
Alternative agents (alphabetical):
- Abatacept, Alemtuzumab
- CNIs (tacrolimus, cyclosporine)
- Etanercept, Extracorporeal photopheresis (ECP)
- Hydroxychloroquine, Imatinib, IL-2
- Low-dose methotrexate
- mTOR inhibitors (sirolimus)
- Mycophenolate mofetil, Pentostatin, Rituximab
Selection of agent should be based on:
- Institutional preferences and physician experience
- Agent's toxicity profile
- Effect of prior treatment
- Drug interactions
- Convenience/accessibility
- Patient tolerability
- Clinical trial enrollment strongly encouraged
---
SUPPORTIVE CARE ESSENTIALS
All patients with GVHD require:
Infection prophylaxis:
- Appropriate antimicrobial prophylaxis with escalating immunosuppression
- CMV reactivation surveillance
- Avoid live vaccines during active GVHD or immunosuppression
- COVID-19 re-vaccination at 3 months post-transplant
Steroid-related monitoring:
- Glucose, blood pressure, bone density (DEXA scan)
- Vitamin D and calcium supplementation
- Monitor for adrenal insufficiency, myopathy, mood changes
Multidisciplinary evaluation:
- Ophthalmology at 6-12 months and ongoing
- Dermatology for advanced skin disease
- Dental for oral GVHD
- GI for esophageal strictures, malabsorption
- Gynecology/urology for genitourinary symptoms
Nutrition:
- Monitor for malnutrition, protein-losing enteropathy
- Trace element deficiencies (magnesium, zinc)
- Vitamin deficiencies (thiamine, B12, D)
- Consider TPN for severe GI GVHD
---
WHO SHOULD FOLLOW THESE PATIENTS? CRITICAL GUIDANCE FOR INTERNATIONAL PATIENTS DISCHARGED FROM NIH OR OTHER TRANSPLANT CENTERS
This is perhaps the most important question for patients who have traveled internationally or across the country for their transplant and are now returning home. Long-term survivorship care requires a coordinated, multidisciplinary approach that cannot be provided by a single physician or specialty.
THE IDEAL CARE MODEL: HYBRID/SHARED CARE
The recommended model is a hybrid or shared care approach where:
1. The transplant center/HCT physician manages transplant-specific complications (GVHD, relapse surveillance, immunosuppression management)
2. The local primary care physician (PCP) provides general medical care, including:
- Surveillance and aggressive management of cardiovascular disease risk factors
- Cancer screening (cervical, colon, breast)
- Screening for diabetes and dyslipidemia
- Vaccination coordination
- Management of chronic conditions
3. Subspecialists provide organ-specific care as needed
MINIMUM FOLLOW-UP SCHEDULE
International consensus guidelines recommend the following minimum schedule:
First 100 days post-transplant:
- Close outpatient follow-up by transplant team
- High risk for readmission due to complications
- Acute GVHD monitoring
Days 100, 180, and 365:
- Comprehensive survivorship visits
- Assessment of GVHD status
- Review of medications and adherence
- Mental health screening
- Physical activity and nutrition counseling
Annually thereafter (lifelong):
- Comprehensive survivorship assessment
- CBC monitoring for at least 10 years
- Cardiovascular risk assessment every 1-3 years (more frequently if high-risk)
- Cancer screening per general population guidelines
- GVHD monitoring and treatment adjustment
REQUIRED MULTIDISCIPLINARY TEAM MEMBERS
For patients with chronic GVHD, the NCCN explicitly states that "multidisciplinary care aimed at avoiding organ damage and preserving function is recommended." This team should include:
Core team:
- HCT physician or hematologist/oncologist familiar with transplant complications
- Primary care physician
- Transplant coordinator/nurse navigator
Organ-specific specialists (as indicated by GVHD involvement):
- Ophthalmologist—beginning 6-12 months post-transplant, ongoing for ocular GVHD
- Dermatologist—for advanced skin GVHD, sclerotic features
- Dentist/oral surgeon—for oral GVHD, suspicious lesions (malignancy risk)
- Gastroenterologist—for esophageal strictures (may need periodic dilation), malabsorption
- Pulmonologist—for bronchiolitis obliterans, restrictive lung disease
- Gynecologist/urologist—for genitourinary GVHD symptoms
- Physical therapist—for musculoskeletal, sclerotic, or neuromuscular disease
- Mental health professional—for psychological adjustment, depression, anxiety
- Nutritionist/dietitian—for malnutrition, weight management
SPECIFIC GUIDANCE FOR INTERNATIONAL PATIENTS DISCHARGED FROM NIH
Before discharge from NIH (or any major transplant center), patients should receive:
1. Comprehensive discharge summary including:
- Transplant details (date, donor type, conditioning regimen)
- GVHD history and current status
- Current immunosuppression regimen with tapering schedule
- Infection prophylaxis requirements
- Vaccination schedule
- Required monitoring (labs, imaging)
- Red flags requiring urgent contact with transplant team
2. Care coordination plan specifying:
- Which provider manages what (transplant team vs. local providers)
- Communication plan between transplant center and local team
- Frequency of required check-ins with transplant team (telemedicine options)
- Laboratory monitoring schedule and where results should be sent
3. Local provider identification before discharge:
- Establish care with local hematologist/oncologist familiar with transplant complications
- Identify local PCP willing to co-manage
- Arrange subspecialty consultations as needed (especially ophthalmology)
Ongoing communication:
- Transplant center should remain available for consultation indefinitely
- Local providers should have direct contact information for transplant team
- Telemedicine visits can facilitate ongoing transplant-specific care
- Annual comprehensive evaluation at transplant center may be beneficial for complex cases
THE REALITY: GAPS IN SURVIVORSHIP CARE
Recent data reveals concerning gaps in post-transplant follow-up:
- Approximately 25% of HCT recipients do not attend a PCP visit in the 5 years before and after transplantation
- This proportion increases to one-third in the fifth year post-HCT
- Among eligible recipients, only 20-25% undergo recommended screening for dyslipidemia and diabetes
- Cancer screening rates are low: 16-18% for cervical cancer, 18-22% for colon cancer, 30-31% for breast cancer
These gaps highlight the critical need for:
- Patient education about long-term risks (cardiovascular disease, secondary malignancies)
- Empowering HCT survivors to actively engage in follow-up care
- Educating PCPs about the unique needs of transplant survivors
- Clear delineation of responsibilities between transplant center and local providers
SPECIAL POPULATIONS REQUIRING SPECIALIZED TEAMS
Certain populations require long-term follow-up with multidisciplinary population-specific teams:
- Hemoglobinopathies ([sickle cell disease](https://www.openevidence.com/rare-disease/sickle-cell-disease), thalassemia)
- Inherited bone marrow failure syndromes
- Inborn errors of immunity
- Metabolic disorders
- Pediatric patients (AYA transition planning)
- Geriatric patients (>65 years)
These patients should maintain connection with specialists familiar with their underlying condition in addition to transplant-related care.
---
THE BOTTOM LINE
GVHD remains the most significant non-relapse complication of allogeneic bone marrow transplantation. Early recognition—starting with the characteristic skin rash—is critical. Eye surgeons must maintain a high index of suspicion for ocular GVHD in any post-transplant patient presenting with dry eye symptoms, as early intervention can prevent irreversible vision loss.
The disease is intimately linked to bone marrow transplant for leukemia, increases in incidence with age, and is driven by a complex immunological cascade that begins with tissue damage and culminates in donor immune cells attacking host organs.
Most importantly, long-term survivorship care cannot be provided by a single physician. International patients discharged from major transplant centers like NIH require a coordinated hybrid care model with clear delineation of responsibilities between the transplant team and local providers. The multidisciplinary team must include—at minimum—an HCT physician, primary care physician, and organ-specific specialists based on GVHD involvement. Ophthalmologic evaluation beginning at 6-12 months post-transplant is mandatory for all allogeneic HCT recipients.
Without this coordinated approach, patients face unacceptably high rates of missed screening, inadequate risk factor management, and preventable complications that can significantly impact both quality of life and long-term survival.
For international patients discharged from centers like NIH. The evidence shows that hybrid/shared care models are essential, with clear roles for transplant physicians, primary care providers, and multiple subspecialists.[1][2][3][4][5]
The NCCN explicitly states that chronic GVHD requires "multidisciplinary care aimed at avoiding organ damage and preserving function," with mandatory involvement of ophthalmology (6-12 months post-transplant), dermatology, dental, GI, pulmonology, gynecology/urology, and physical therapy as clinically indicated.[6] Unfortunately, recent data shows that 25-33% of transplant survivors don't even see a PCP regularly, and screening rates for cardiovascular disease and cancer are alarmingly low (16-31%), highlighting the urgent need for better care coordination.[4]
For international patients, the key is establishing this multidisciplinary team before discharge with clear communication pathways between the transplant center and local providers, ideally supplemented by telemedicine for ongoing transplant-specific management.[2][3][5]
References
1. Assessment of Survivorship in Allogeneic Hematopoietic Stem Cell Transplantation. McErlean G. Methods in Molecular Biology (Clifton, N.J.). 2025;2907:91-125. doi:10.1007/978-1-0716-4430-0_5.
2. International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update. Rotz SJ, Bhatt NS, Hamilton BK, et al. Transplantation and Cellular Therapy. 2024;30(4):349-385. doi:10.1016/j.jtct.2023.12.001.
3. Long-Term Follow-Up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics. Saunders IM, Tan M, Koura D, Young R. Pharmacotherapy. 2020;40(8):808-841. doi:10.1002/phar.2443.
4. Primary Preventive Care of Hematopoietic Stem Cell Transplantation Survivors: Time to Educate and Empower Recipients and Providers. Fulcher J, Blanchard AP, Bredeson C, van Walraven C. Transplantation and Cellular Therapy. 2023;29(2):131.e1-131.e6. doi:10.1016/j.jtct.2022.10.028.
5. International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update. Rotz SJ, Bhatt NS, Hamilton BK, et al. Bone Marrow Transplantation. 2024;59(6):717-741. doi:10.1038/s41409-023-02190-2.
6. Hematopoietic Cell Transplantation. National Comprehensive Cancer Network. Updated 2025-09-24.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.